Drug intelligence / Profile preview

REG-001

Development stage: Preclinical
Lead developer: Regenica Biosciences
Modality: Small Molecules

Overview

REG-001 is a small molecule therapeutic candidate being developed by Regenica Biosciences as an antidote for organophosphate poisoning, including exposure to chemical nerve agents and insecticides. Developed by scientific founders including Nobel laureate Barry Sharpless and Palmer Taylor, the drug is specifically engineered to cross the blood-brain barrier, a significant improvement over current standard-of-care treatments like pralidoxime (2-PAM) which have limited central nervous system penetration. By reaching the brain, REG-001 can reactivate acetylcholinesterase and prevent the life-threatening seizures and long-term neurological damage typically associated with organophosphate toxicity. The compound was in preclinical development as of 2019.

Other names: ReGenica

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on REG-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REG-001.

Explore the full profile